Absci Corp
Research Absci Corp (ABSI) on Bullrun: market cap USD 1.74B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerABSI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.74B
- Financial periodQ2 2026
- RevenueUSD 318.00K
- Net income-USD 33.21M
- Free cash flow-USD 27.57M
Valuation Snapshot
latest market cap is USD 1.74B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.80M | -USD 115.18M | -USD 94.03M | n/a | -0.84 | USD 20.03M | USD 5.30M | USD 189.45M |
| FY2024 | USD 4.53M | -USD 103.11M | -USD 72.81M | n/a | -0.94 | USD 41.21M | USD 3.99M | USD 179.13M |
| FY2023 | USD 5.72M | -USD 110.57M | -USD 65.50M | n/a | -1.2 | USD 72.36M | USD 7.92M | USD 176.18M |
| FY2022 | USD 5.75M | -USD 104.90M | -USD 97.51M | n/a | -1.15 | USD 59.96M | USD 10.93M | USD 274.41M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 1.74B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 528.79M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 302.25M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 390.34M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 194.03M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 759.71M | n/a | n/a | n/a |
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
ETFs that hold Absci Corp
Absci Corp is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| ARK Genomic | 5.17% | 0.75% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Absci Corp's market cap?
Absci Corp's market capitalization is USD 1.74B.
What does Absci Corp do?
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.